Metacare (118000) Fundamentals 2026 — P/E 39.3x, Revenue Analysis | SniperIQ
Metacare (118000) is a KR-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₩22.3B, trading at ₩1300.00 on the KSC. This SniperIQ fundamentals page covers Metacare's valuation (P/E 39.3x, P/B 0.2x), profitability (net margin 1.5%), revenue (₩32.8B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Metacare's market cap?
Metacare (118000) has a market capitalization of approximately ₩22.3B, trading at ₩1300.00 on the KSC. Market cap moves with the live share price.
What is Metacare's P/E ratio?
Metacare's trailing twelve-month P/E ratio is 39.3x, with a price-to-book (P/B) of 0.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Metacare?
Metacare runs a net profit margin of 1.5%, a gross margin of 23.3%, and an operating margin of 3.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Metacare generate?
Metacare reported revenue of ₩32.8B for fiscal year 2025, with net income of ₩498M and earnings per share (EPS) of 29.57. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Metacare pay a dividend?
Metacare does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Metacare financially healthy?
Metacare carries a debt-to-equity ratio of 0.44x and a current ratio of 0.32x, with a market beta of 0.58. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Metacare a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Metacare (118000) the key facts are: market cap ₩22.3B, P/E 39.3x, revenue ₩32.8B, 52-week range 1001-4090. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Metacare's full fundamentals live
Get Metacare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.